Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28841074 | 0.89 | KCNH2 (0.46) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL17726436 | 0.85 | CHRM2 (0.55) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL30922323 | 0.85 | PRKCI (0.51) | PRKCIRAB9ANPC1POLB | |
| SCHEMBL317341 | 0.85 | PRKCI (0.51) | PRKCIRAB9ANPC1POLB | |
| SCHEMBL18101234 | 0.83 | KCNH2 (0.40) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL4031191 | 0.81 | CA12 (0.38) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL24459645 | 0.81 | CHRM2 (0.50) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL2632210 | 0.81 | CHRM2 (0.50) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL292129 | 0.81 | CHRM2 (0.50) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL8167072 | 0.81 | CHRM2 (0.54) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4644390-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| CN-119192105-A | Process for the preparation of 6-benzofuranols | 安徽昊帆生物有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024140850-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 苏州必扬医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| EP-2789606-A1 | Modulators of CFTR | Vertex Pharmaceuticals Incorporated (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2164840-A2 | MODULATORS OF CFTR | Vertex Pharmaceuticals Incorporated (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1369490-B1 | Method of preparing a composition containing hygromycin A and epi-hygromycin | PFIZER PROD INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1369490-A1 | Method of preparing a composition containing hygromycin A and epi-hygromycin | Pfizer Products Inc. (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1075483-B1 | HYGROMYCIN A DERIVATIVES | PFIZER PROD INC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-6313100-B1 | ANTIBACTERIAL, ANTIPROTOZOA AGENTS | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1075483-A2 | HYGROMYCIN A DERIVATIVES | Pfizer Products Inc. (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999057125-A2 | HYGROMYCIN A DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166516-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | CHRM2 2222/4885CHRM1 3155/4885CHRNB2 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.